Sign in
Taking people in French GuianaPhase 2

Split daily doses of hydroxycarbamide for children with sickle cell disease

Tests split-dose hydroxycarbamide in children with sickle cell disease.

Key facts

Who runs it
Theravia
Where
Cayenne, French GuianaSee the siteAlso in 1 other country, 6 sites
Trial code
Registry title
Pharmacokinetics, Efficacy and Safety of Twice Daily Dosing Regimen of Hydroxycarbamide Dispersible Tablets in Children With Sickle Cell Disease
Status
Recruiting
Phase
Phase 2
People taking part
50 people, planned
Started
21 Jan 2025
Expected to end
Feb 2028
Type of study
Interventional
Treatments tested
  • Hydroxycarbamid
Record updated
1 October 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for children with sickle cell disease (HbSS or HbSβ0) aged 9 months to 11 years who have never taken hydroxycarbamide. They take it twice a day for 12 months.

Age
9 months to 11 years
Sex
Girls and boys can join.
Disease stage
Sickle cell disease of type HbSS or HbSβ0. Children over 18 months need a transcranial Doppler in the last 12 months showing low risk for stroke.
Earlier treatment
Must never have taken hydroxycarbamide. No regular blood transfusions or any transfusion in the last 3 months. No other treatments that change sickle cell disease.
Biomarker or test result
Absolute neutrophil count ≥ 1.0x109/L, platelets ≥ 75x109/L and haemoglobin > 5.5 g/dL.

Main reasons for not taking part

  • Took part in another drug study in the last 4 weeks
  • Chronic kidney disease stage 3, 4 or 5
  • Known HIV, hepatitis B or hepatitis C infection
  • Stroke or bleeding inside the skull in the past, or an unchecked nervous system finding in the last 12 months
  • Pregnant or breastfeeding

The registry criteria, word for word

Show all 18 criteriaShow less

Who can take part

  • Written informed consent, signed and dated by both parents or by the legally acceptable representative(s) of the children, and, if possible, assent from the children,
  • HbSS or HbSβ0 SCD,
  • Aged between 9 months and 11 years old,
  • Hydroxycarbamide naïve,
  • Parent(s) or legally acceptable representative(s) capable of communicating with the investigator and understanding the requirements and constraints of the study protocol and willing to comply with the study requirements,
  • Contraception criterion, if applicable: for patients who are sexually active
  • Affiliated to a social security plan or beneficiary of a similar insurance plan,
  • Patient must meet the following laboratory values : Absolute Neutrophil Count ≥ 1.0x109/L, Platelets ≥ 75x109/L and Haemoglobin (Hgb) > 5.5 g/dL,
  • Transcranial Doppler (TCD) in the last 12 months indicating low risk for stroke is required for children over 18 months of age

Who cannot take part

  • Patients treated with other SCD-modifying therapies,
  • Patient with a stage 3, 4 or 5 chronic kidney disease,
  • Patients known to be infected with human immunodeficiency virus, hepatitis B virus, or hepatitis C virus,
  • Known hypersensitivity or allergy to the excipients,
  • Any surgical or medical condition or any significant illness that, in the opinion of the investigator, constitutes a risk or a contraindication to the participation of the patient to the study, or that may interfere with the objectives, conduct or evaluation of the study,
  • Any documented history of a clinical stroke or intracranial haemorrhage, or an uninvestigated neurologic finding within the past 12 months
  • Participation in any other clinical study for any other pharmaceutical product within 4 weeks preceding the inclusion visit,
  • Patients who have had chronic blood transfusion or transfusion in the last 3 months preceding the inclusion visit,
  • Female patients who are pregnant or lactating,

Where in French Guiana

Also in 1 other country, 6 sites

  • Centre Hospitalier de CayenneCayenne, French GuianaContact: Narcisse Elenga, MD, PhDTaking people

About the trial

What the trial wants to find out

The purpose of this interventional, phase II, national, multicentric, non-randomised, open-label study is to evaluate the pharmacokinetics (PK), efficacy and safety of Hydroxycarbamide Paediatric dispersible tablets with a twice daily dosing regimen in children with Sickle Celle Disease between 9 months to 11 years of age.

Read full original descriptionShow less

Participants will:

* Take Hydroxycarbamide twice a day every day for 12 months * Visit the clinic at screening, baseline, 1, 3, 6, 9 and 12 months

The group in the trial

  • Hydroxycarbamide Pediatric dispersible tabletTreatment being tested

    Hydroxycarbamide Pediatric dispersible tablet will be administered twice daily during 12 months.

    Treatment: Hydroxycarbamid

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Pharmacokinetics, Efficacy and Safety of Twice Daily Dosing Regimen of Hydroxycarbamide Dispersible Tablets in Children With Sickle Cell Disease: a Single-group, Non-randomised, Open-label Study (KID-BID)
Plain-language title
Split daily doses of hydroxycarbamide for children with sickle cell diseaseGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
1 October 2026